| Literature DB >> 33134535 |
Tess M McLaughlin1,2, Jane J Broadhurst1,2, Courtenay J Harris1, Sarah McGarry1, Sharon L Keesing1.
Abstract
BACKGROUND: The purpose of this pilot trial was to determine the feasibility of a self-managed lymphedema randomized control trial to test the effectiveness of a head and neck-specific exercise protocol.Entities:
Keywords: head; lymphedema; neck; self‐management; treatment
Year: 2020 PMID: 33134535 PMCID: PMC7585235 DOI: 10.1002/lio2.455
Source DB: PubMed Journal: Laryngoscope Investig Otolaryngol ISSN: 2378-8038
FIGURE 1Study flow chart of participants
Demographic characteristics of participants at baseline
| Demographic characteristics | Total sample (n = 9) | Control group (n = 4) | Intervention group (n = 5) | Significance ( |
|---|---|---|---|---|
| Age, years | .712 | |||
| Mean | 62 | 61 | 63 | |
| Median | 66 | 66.5 | 63 | |
| Range | 35‐76 | 35‐76 | 58‐69 | |
| SD | 11.5 | 17.9 | 4.6 | |
| Sex | .167 | |||
| Male, number (%) | 6 (67) | 4 (100) | 2 (33) | |
| Female, number (%) | 3 (33) | 0 (0) | 3 (100) | |
| Cancer type, number (%) | .444 | |||
| Squamous cell carcinoma | 8 (89) | 3 (75) | 5 (100) | |
| Adenoid cystic carcinoma | 1 (11) | 1 (25) | 0 (0) | |
| Cancer location, number (%) | .524 | |||
| Oropharyngeal | 4 (44) | 1 (25) | 3 (60) | |
| Oral cavity | 1 (11) | 0 (0) | 1 (20) | |
| Salivary | 1 (11) | 1 (25) | 0 (0) | |
| Laryngeal | 1 (11) | 0 (0) | 1 (20) | |
| Infraorbital | 1 (11) | 1 (25) | 0 (0) | |
| Hypopharyngeal | 1 (11) | 1 (25) | 0 (0) | |
| Lymph node removal | ||||
| No | 6 (67) | 3 (50) | 3 (50) | 1.0 |
| Yes | 3 (33) | 1 (33) | 2 (67) | |
| Unilateral | 1 (33) | 1 (100) | 0 (0) | .333 |
| Bilateral | 2 (67) | 0 (0) | 2 (100) | |
| Radiotherapy | ||||
| External beam | 9 (100) | 4 (100) | 5 (100) | 1.0 |
| Mean total dose | 2 Gy | 2 Gy | 2 Gy | 1.0 |
| Dose range | 60‐70 Gy | 60‐70 Gy | 66‐70 Gy | .314 |
| Unilateral | 2 (22) | 2 (50) | 0 (0) | .167 |
| Bilateral | 7 (78) | 2 (50) | 5 (100) | |
| Cancer treatment received, number (%) | 1.0 | |||
| Radiotherapy | 1 (11) | 1 (25) | 0 (0) | |
| Chemotherapy and radiotherapy | 5 (56) | 2 (50) | 3 (60) | |
| Radiotherapy and surgery | 2 (22) | 1 (25) | 1 (20) | |
| Radiotherapy, chemotherapy, and surgery | 1 (11) | 0 (0) | 1 (20) | |
| Time since cancer treatment, number (%) | .333 | |||
| 1‐4 weeks | 1 (11) | 0 (0) | 1 (20) | |
| 1‐3 months | 4 (44) | 3 (75) | 1 (20) | |
| 3‐6 months | 4 (44) | 1 (25) | 3 (60) | |
| MD Anderson Cancer Center Rating Scale, number (%) | 1.0 | |||
| 2 (firm pitting edema, not reversible with no tissue changes) | 4 (44) | 2 (50) | 2 (40) | |
| 1b (soft pitting edema, reversible) | 5 (55.6) | 2 (50) | 3 (60) | |
| Living distance from hospital (km) | .624 | |||
| Mean | 167.6 | 100.65 | 220.82 | |
| Median | 38.5 | 29.8 | 65 | |
| Range | 16‐766 | 16‐324 | 16.1‐766 | |
| SD | 250.4 | 317.3 | 149.2 |
Time from radiation treatment
| Participant | Surgical lymph node dissection | No. of radiotherapy treatments | Time from cancer treatment, months |
|---|---|---|---|
| 1 | No | 35 (70 Gy) | 6 months |
| 2 | No | 35 (70 Gy) | 3 months |
| 3 | Unilateral | 33 (66 Gy) | 3 months |
| 4 | Bilateral | 33 (66 Gy) | Still undergoing radiation |
| 5 | No | 35 (70 Gy) | 6 months |
| 6 | Bilateral | 33 (66 Gy) | 5 months |
| 7 | No | 33 (66 Gy) | 3 months |
| 8 | No | 30 (60 Gy) | 7 months |
| 9 | No | 35 (70 Gy) | 3 months |
Abbreviation: Gy, Gray.
FIGURE 2Control group compression use from baseline to follow‐up
FIGURE 3Intervention group compression use from baseline to follow‐up
FIGURE 4Intervention group frequency of exercise protocol from baseline to follow‐up
Individual participant scores for the control and intervention groups on lymphedema measures at baseline (T0) and follow‐up (T1)
| Recruitment order | Group allocation | ALOHA measurements | MDACC HNL Rating Scale | ||
|---|---|---|---|---|---|
| Upper neck circumference, cm | Lower neck circumference, cm | Ear to ear measurement, cm | MDACC HNL Rating Scale | ||
| T0, T1 (diff) | T0, T1 (diff) | T0, T1 (diff) | T0, T1 (diff) | ||
| 1 | INT | 46.0, 46.5 (+0.50) | 42.5, 43.1 (+0.60) | 28.0, 27.1 (−0.90) | 1b, 1b (0) |
| 2 | CON | 44.5, 44.5 (0) | 42.3, 43.0 (+0.70) | 26.0, 27.0* (+1.00) | 1b, 1b (0) |
| 3 | CON | 43.5, 43.5 (0) | 44.0, 43.3 (−0.70) | 29.0, 27.0 (−2.00) | 2, 1b (−1) |
| 4 | INT | 41.0, 44.6 (+3.60) | 39.4, 42.1 (+2.70) | 26.3, 27.0 (+0.70) | 2, 2 (0) |
| 5 | INT | 38.3, 37.5 (−0.80) | 38.1, 37.1 (−1.00) | 24.6, 24.5 (−0.10) | 1b, 1a (−1) |
| 6 | INT | 35.0, NR | 34.1, NR | 23.5, NR | 2, NR |
| 7 | CON | 53.0, 48.0 (−5.00) | 46.0, 43.6 (−2.40) | 26.0, 25.8 (−0.20) | 1b, 1b (0) |
| 8 | CON | 45.1, 42.3 (−2.80) | 37.4, 36.5 (−0.90) | 25.3, 25.1 (−0.20) | 2, 2 (0) |
| 9 | INT | 45.2, 41.8 (−3.40) | 43.0, 42.2 (−0.80) | 29.0, 28.6 (−0.40) | 1b, 1b (0) |
Abbreviations: ALOHA, assessment of lymphedema of the head and neck; (diff), difference; MDACC HNL, MD Anderson Cancer Center Head and Neck Lymphedema; NR, not recorded; T0, baseline; T1, follow‐up.
Participant demonstrated a negative change from baseline to follow‐up.
Within group differences on lymphedema and patient reported measures: P‐value
| ALOHA measurements | MDACC HNL Rating Scale | EORTC QLQ‐H&N43 | |||||
|---|---|---|---|---|---|---|---|
| Group allocation | Upper neck circumference | Lower neck circumference | Ear to ear measurement | MDACC HNL Rating Scale | QOL | Swallowing | Body image |
| CON | 0.317 | 0.180 | 0.197 | 0.461 | 0.102 | 0.109 | 0.317 |
| INT | 1.000 | 1.000 | 0.465 | 0.317 | 0.109 | 0.414 | 0.414 |
Abbreviations: ALOHA, assessment of lymphedema of the head and neck; CON, active control group; EORTC QLQ‐H&N43, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Head and Neck Module; INT, intervention group; MDACC HNL, MD Anderson Cancer Centre Head and Neck Lymphedema; QOL, quality of life.